Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SUNRISE: Tezepelumab in Oral Corticosteroid Dependent Asthma
NCT05398263Phase 3Terminated
- Sponsor
- AstraZeneca
- Start
- Aug 2022
- Primary completion
- Mar 2025
- Modality
- Monoclonal Antibodies
- Countries
- 12
01
Overview
A Phase 3 trial of tezepelumab in asthma, sponsored by AstraZeneca. Started Aug 2022; status: terminated.
02
Drugs
03
Conditions
asthma
Beyond the preview
Go deeper on NCT05398263.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05398263.